Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Clinical Pharmacology Publications – 2012

2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995

  • Zhang M, Moore GA, Fernyhough LJ, Barclay ML, Begg EJ. Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. Anal Bioanal Chem 2012; 404(6-7), 2091-6 [Abstract]
  • Campbell K, Doogue M. Evaluating and managing patients with thyrotoxicosis. Aust Fam Physician 2012; 41(8), 564-72 [Abstract]
  • Eglinton TW, Roberts R, Pearson J, Barclay M, Merriman TR, et al. Clinical and genetic risk factors for perianal Crohn’s disease in a population-based cohort. Am J Gastroenterol 2012; 107, 589-96 [Abstract]
  • Snyder BD, Polasek TM, Doogue MP. Drug interactions: principles and practice. Aust Prescr 2012; 35(3), 85-8 [Abstract]
  • Barclay M, van Egmond R, Chin P. TPMT – not all that glitters is gold; author’s reply. Aliment Pharmacol Ther 2012; 36, 209-10 [Abstract]
  • van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther 2012; 35(10), 1181-9 [Abstract]
  • Begg EJ, Chin PKL. A unified pharmacokinetic approach to individualised drug dosing. Br J Clin Pharmacol 2012; 73(3), 335-9 [Abstract]
  • Jensen BP, Roberts RL, Vyas R, Bonke G, Jardine JL, Begg EJ. Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortiptyline-induced postural hypotension in healthy volunteers. Br J Clin Pharmacol 2012; 73(4), 619-28 [Abstract]
  • Jensen BP, Chin PKL, Roberts RL, Begg EJ. Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin. Br J Clin Pharmacol 2012; 74(5), 797-805 [Abstract]
  • Chin PKL, Vella-Brincat JWA, Barclay ML, Begg EJ. Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? Br J Clin Pharmacol 2012; 74(5), 734-40 [Abstract]
  • Chin PKL, Barclay ML, Begg EJ. Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring (Letter). Br J Clin Pharmacol 2012; 75(2), 554-5 [Abstract]
  • Vella-Brincat J, MacLeod R, MacLeod S. The palliative care handbook. (Book) 2012, 6th edition [Ref]
  • Campbell KA, Joseph SP, Whiting MJ, Doogue MP. The author’s reply: the half-lives of plasma free metanephrines. Clin Endocrinol 2012; 77(3), 486-5 [Abstract]
  • Young SW, Zhang M, Freeman JT, Vince KG, Coleman B. Higher cefazolin concentrations with intraosseous regional prophylaxis in TKA. Clin Orthop Relat Res 2012; 470(7) [Abstract]
  • Eglinton TW, Barclay ML, Gearry RB, Frizelle FA. The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum 2012; 55(7), 773-7 [Abstract]
  • Snyder B, Polasek TM, Doogue MP. Reply to: Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2012; 14(7), 670 [Abstract]
  • Roberts RL, Diaz-Gallo LMD, Barclay ML, Gomez-Garcia M, et al. Independent replication of an association of CNVR7113.6 with Crohn’s disease in Caucasians. Inflamm Bowel Dis 2012; 18(2), 305-11 [Abstract]
  • Joseph SP, Ho JT, Doogue MP, Burt MG. Perioperative management of the hypothalamic-pituitary-adrenal axis in patients with pituitary adenomas: an Australasian survey. Intern Med J 2012; 42(10), 1120-4 [Abstract]
  • Chin PKL, Vella-Brincat JWA, Begg EJ. Clarifying the American Society of Clinical Oncology practice guideline for chemotherapy dosing for obese adults. J Clin Oncol 2012; 30(31), 3897 [Abstract]
  • Roberts RL, Barclay ML. Current relevance of pharmacogenetics in immunomodulation treatment for Crohn’s disease. J Gastroenterol Hepatol 2012; 27(10), 1546-54 [Abstract]
  • Currow DC, Vella-Brincat J, Fazekas B, Clark K, Doogue M, Rowett D. Pharmacovigilance in hospice/palliative care: Rapid report of net clinical effect of metoclopramide. J Palliat Med 2012; 15(10), 1071-5 [Abstract]
  • Currow DC, Rowett D, Doogue M, To THM, Abernathy AP. An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. J Palliat Med 2012; 15(3), 282-6 [Abstract]
  • Vella-Brincat JWA, Begg EJ, Jensen BP, Chin PKL, Roberts RL. The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. J Pain Symptom Manage 2012; 43(3), 540-8 [Abstract]
  • Fairhall M, Reid K, Vella-Brincat JWA, Walker J, Chin PKL, Begg EJ, et al. Exploring hospice patients’ views about participating in research. J Pain Symptom Manage 2012; 43(3), e9-e11 [Abstract]
  • Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Doogue MP, et al. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust 2012; 197(4), 224-5 [Abstract]
  • McKean A, Vella-Brincat J. Is it NICE to monitor lithium routinely? NZ Med J 2012; 125(1355), 50-4 [Abstract]
  • Ellis E, Chin PK, Hunt PJ, Hunt H, Lewis JG, Soule SG. Is late-night salivary cortisol a better screening test for possible cortisol excess than standard screening tests in obese patients with type 2 diabetes. NZ Med J 2012; 125(1353), 47-58 [Abstract]
  • Begg EJ, Helsby NA, Jensen BP. Pharmacogenetics of drug-metabolising enzymes: the prodrug hypothesis. Pharmacogenomics 2012; 13(1), 83-9 [Abstract]
  • Kennedy MA, Joyce PR, Begg EJ. Institutional Profile: The Carney Centre for Pharmacogenomics: a New Zealand focus for personalised medicine research. Pharmacogenomics 2012; 13(8), 865-8 [Abstract]
  • Macleod AD, Vella-Brincat JWA. Cachexia, depression, and sickness behaviour. Prog Palliat Care 2012; 20(3), 163-8 [Abstract]
  • Stamp LK, Barclay ML, O’Donnell JL, Zhang M, Drake J, Frampton C. Furosemide increases plasma oxypurinol without lowering serum urate – a complex drug interaction: implications for clinical practice. Rheumatology 2012; 51(9), 1670-6 [Abstract]
  • Doogue MP, Burt MG. Chapter 43 - Miscellaneous hormones. Side Effects of Drugs Annual 2012; 34, 703-22 [Abstract]
  • Wigg A, Chaudhary S, Mccormick R, Woodman R, Wundke R, Doogue M. Prevalence of low bone density states and vitamin D deficiency in a large cohort of cirrhotic patients. J Gastroenterol Hepatol 2012; 27, 93-4 [Abstract]
  • To T, Agar M, Shelby-James T, Abernathy A, Doogue M, et al. Off-label prescribing in palliative care: a cross-sectional national survey of Australian palliative medicine doctors. J Palliat Care 2012; 28(3), 189-90 [Abstract]
  • Stranks S, Doogue M. Using HbA1c to test for undiagnosed diabetes. Health Publish Aust 2012; 39, 10 [Abstract]
  • Burt M, Magelsdorf B, Whiting M, Doogue M, et al. Comparison of immunoassay and mass spectrometry measurement of cortisol during ACTH1-24 stimulation tests. 15th International and 14th European Congress of Endocrinology 2012; 29, 1476 [Abstract]